This study assessed the safety and efficacy of recombinant human interleukin (rhIL)-11 in decreasing platelet transfusion requirements in patients with breast cancer who were undergoing autologous bone marrow transplantation (ABMT) with peripheral blood progenitor cell (PBPC) support. After high-dose therapy with cyclophosphamide, cisplatin, and carmustine, 80 patients were randomized to one of three treatment groups: placebo (26), 25 µg/kg of rhIL-11 (28), and 50 µg/kg of rhIL-11 (26). Of those randomized, 75 (94%) received at least one dose of the masked study drug and the remaining 5 (6%) withdrew consent before study drug administration. In the placebo group, each patient received an average 12.4 (؎10.2) platelet transfusions vs. 9.2 (؎5.0) in the 25-g/kg rhIL-11 group ( p ‫؍‬ 0.17) and 9.9 (؎3.5) in the 50-g/kg rhIL-11 group ( p ‫؍‬ 0.34). There was no statistically significant difference between the rhIL-11 groups and the placebo group in the median number of days to platelet recovery. Neutrophil and red blood cell recovery were similar for all treatment groups. The imbalance in the number of patients already alloimmunized at study entry in the rhIL-11 groups (12) and in the placebo group (1) may have confounded the primary efficacy assessment. Most adverse events were related to the high-dose chemotherapy. Generally mild edema and minor conjunctival bleeding (grades 1 or 2) were statistically associated with rhIL-11 administration ( p Ͻ 0.04). There was no association between rhIL-11 and the occurrence of atrial arrhythmias, although there was a suggestion of an association with rhIL-11, 5 of 50 cases vs. 1 of 25 in the placebo group. Two cardiovascular events, tachycardia and hypotension (grade 1 or 2), occurred in the 50-g/kg rhIL-11 group. The number of patients who discontinued study drug dosing because of an adverse event was distributed across all treatment groups. In summary, rhIL-11 was safe and well tolerated in this study. The results did not demonstrate that rhIL-11 treatment significantly decreased platelet transfusion requirements after high-dose chemotherapy with ABMT and PBPC support.
INTRODUCTION
High-dose chemotherapy with hematopoietic support is an effective therapy for many malignancies, including Hodgkin's disease, non-Hodgkin's lymphoma, and acute myeloid leukemia and is gaining wide acceptance in the treatment of breast cancer. Over the past decade, autologous bone marrow transplantation (ABMT) has allowed the use of high-dose chemotherapy regimens in patients with metastatic breast cancer or high-risk primary breast cancer [1, 2] . Nonrandomized uncontrolled studies using such regimens have found improvements in response rate, median survival, and disease-free survival [1, 3] . However, high-dose A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer
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chemotherapy regimens, particularly with alkylating agents, often cause severe thrombocytopenia. Typically, patients undergoing ABMT need platelet transfusions for periods of weeks to, occasionally, months.
In recent studies, ABMT has been supplemented by the administration of autologous peripheral blood progenitor cells (PBPC), collected by cytapheresis following "mobilization" with chemotherapeutic agents or hematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF). This regimen has shortened the period of platelet transfusion dependence resulting from the high-dose chemotherapy, with the result that patients can be discharged earlier. At Duke University, patients treated with cyclophosphamide, cisplatin, and carmustine (BCNU) followed by ABMT and PBPC infusions required an average of 9.6 transfusions [4] .
Platelet transfusions are costly and associated with risks of alloimmunization, transmission of infectious disease, and transfusion reactions. Therefore, we investigated a novel thrombopoietic factor, recombinant interleukin (rhIL-)11 (Neumega, Genetics Institute, Cambridge, MA) [5] , which has been shown to stimulate both murine and human megakaryocytopoiesis [6] [7] [8] , increase platelet production in a variety of animal species, and accelerate the recovery of platelet counts following myelosuppressive chemotherapy in mice [9] . These results from animal studies were borne out in clinical trials. In a dose-escalating study, rhIL-11 (10, 25, 50 , and 75 g/kg once daily) was administered subcutaneously (SC) for up to 28 days to patients with high-risk breast cancer, who were undergoing ABMT and intensive myelosuppressive chemotherapy [10] . On average, patients required fewer platelet transfusions and had earlier platelet recovery with increasing doses of rhIL-11.
This report describes the results of a phase II study of rhIL-11 (25 and 50 g/kg) vs. placebo, which was undertaken to learn whether rhIL-11 would decrease the use of platelet transfusions and accelerate platelet recovery in patients with breast cancer who were undergoing high-dose chemotherapy with ABMT and PBPC support.
MATERIALS AND METHODS

Selection of patients
Women with pathologically confirmed breast cancer (stage II or IIIA with Ն4 positive nodes or stage IIIB or IV) were eligible to participate in the study if they were at least 18 years old; had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; had normal respiratory, cardiac, hepatic, and renal function; and had no child-bearing potential or were practicing a medically approved method of contraception at the time of study entry and continued to do so for the duration of the study. All patients were required to give written informed consent, and the protocol was approved by the Institutional Review Board of the Duke University Medical Center. The patients received three or four cycles of doxorubicin-based induction chemotherapy followed by highdose chemotherapy and hematopoietic support.
Patients were excluded if they had a history of metastatic disease in the central nervous system, deep-vein thrombosis, pulmonary embolus, stroke, transient ischemic attacks or other thromboembolic disease within the past 6 months, or atrial fibrillation or conditions known to predispose to atrial fibrillation. Patients who had undergone bone marrow or peripheral stem cell harvest purged with monoclonal antibodies or chemotherapy in vitro, had experienced clinically evident hemolytic anemia or significant bleeding, or had used aspirin or nonsteroidal anti-inflammatory agents within 1 week before study entry also were not allowed to enter the study. In addition, patients with known hypersensitivity to any Escherichia coli protein who were seropositive for human immunodeficiency virus and who were pregnant or breast feeding were excluded.
Study medication
Recombinant human interleukin 11 (Neumega rhIL-11 Growth Factor), derived from genetically altered Escherichia coli, was provided by Genetics Institute. rhIL-11 was provided as a lyophilized powder in labeled vials. Each vial was reconstituted with 1 mL of sterile water for injection. The final concentration of rhIL-11 after reconstitution was 5.0 mg/mL (pH 7.0).
Study design
This randomized double-blind study compared two doses of rhIL-11 (25 or 50 g/kg) vs. placebo in women with breast cancer who were undergoing high-dose chemotherapy with autologous bone marrow transplantation and PBPC support (Fig. 1 ). Patients were randomized to one of three treatment groups: rhIL-11 25 g/kg SC once daily, rhIL-11 50 g/kg SC once daily, or placebo. Because the volumes of the lower and higher doses of rhIL-11 were different, patients who were assigned to the placebo group received either a lower (0.005 mL/kg) or higher (0.01 mL/kg) volume of placebo. This procedure ensured that masking was maintained. rhIL-11 was administered as a daily SC injection for 7-21 days, according to the criteria below (platelet count Ͼ20,000 for two consecutive days independent of transfusion). Patients received preparative chemotherapy, which consisted of cyclophosphamide (1875 mg/M 2 /day intravenously [IV] over 1 hour) and cisplatin (55 mg/M 2 /day IV as a continuous infusion), each administered on the fifth, fourth, and third days before study drug administration (days Ϫ6, Ϫ5, and Ϫ4), and carmustine (600 mg/M 2 at a rate of 5 mg/M 2 /minute), administered on the second day before study drug administration (day Ϫ3). The rh-IL11 was begun on day Ϫ1, the first day of PBPC infusion, and continued until the platelet count was Ͼ20,000 for 2 consecutive days, independent of transfusions.
Platelet counts were monitored daily. To minimize the risk of hemorrhagic myocarditis due to platelet dysfunction caused by high-dose chemotherapy [4] , two bags of singledonor platelets (i.e., two platelet transfusions) were given to each patient the day before the first reinfusion and study drug administration (day Ϫ2), regardless of the patient's platelet count. In patients not refractory to platelet transfusions, during the first 12 days after completion of hematopoietic stem cell infusions, platelets were transfused for a platelet count of Ͻ25,000 cells/µL. Subsequently, platelets were transfused if the count was Ͻ15,000 cells/L. For counts between 15,000 and 25,000 cells/L after day 12, patients were transfused only if the absolute neutrophil count (ANC) was Ͻ500 cells/L. All platelet transfusions were single-donor pheresed platelets. Patients refractory to platelet transfusions (i.e., with posttransfusion increases in platelet counts under 5000 L) were transfused only if their platelet counts dropped below 5000 L at any time. Every platelet transfusion was followed by a 1-hour posttransfusion platelet count. Patients had a human leukocyte antigen (HLA) cytotoxic antibody panel, and patients with Ͼ15 of 30 positive wells were considered alloimmunized. Patients who were alloimmunized and had a post-platelet transfusion increment of Ͼ5000 L received HLA-matched platelets.
Patients were diuresed to maintain their baseline weight. If a patient's serum potassium concentration was Ͻ4.0 mEq/L, the patient was given potassium supplements with the goal of maintaining a serum potassium concentration Ն4.0 mEq/dL.
All patients received a standard prophylactic antibiotic regimen consisting of ciprofloxacin 500 mg by mouth every 8 hours and rifampin 300 mg by mouth every 12 hours, beginning on day Ϫ2. Febrile neutropenia and other infections were treated according to standard practice at Duke University.
Safety was assessed on the basis of the number of patients reported to be experiencing adverse events, the severity of adverse events, the time course of ANC recovery, red blood cell (RBC) transfusions, changes in laboratory test results, and the number of patients with tumor progression. In addition, Holter monitoring was performed before the first PBPC reinfusion/study drug dose and continued for 72 hours. Subsequently, 24-hour Holter monitoring was performed again on days 8 and 16.
Before entry into the study, patients had a complete medical history, physical examination, and laboratory evaluations, including complete blood counts, serum chemistry tests, coagulation studies, urinalysis, chest X ray, and electrocardiogram. A follow-up physical examination was carried out 6 weeks after ABMT.
Blood specimens to measure platelet reticulocytes were drawn daily, beginning on day Ϫ2. Platelet reticulocyte counts were determined by flow cytometric analysis after staining with thiazole orange (Reticcount, Becton Dickinson Immunocytometry Systems, Mountainview, CA), as previously described [11] . Briefly, patient blood samples were collected into edetic acid anticoagulant, and platelet-rich plasma (PRP) was prepared by centrifugation. An aliquot of PRP was fixed with 1% paraformaldehyde, then a subaliquot was incubated with the thiazole orange reagent for 30 minutes in the dark. Patient samples were analyzed on a FACScan flow cytometer (Becton Dickinson, San Jose, CA) and compared with three or four normal control samples run with each assay. Those platelets exhibiting fluorescence greater than two standard deviations (SD) above the mean of the normal control platelet distributions were designated as "reticulated platelets."
Statistical analyses
The primary end points for evaluating safety were the incidence and severity of reported adverse events and the laboratory test results from all patients. Because the differences between the rhIL-11 treatment groups were not clinically significant, these groups were combined and contrasted with the placebo group using Fisher's exact test, with p Ͻ 0.05 being the significance threshold.
The primary efficacy outcome measure for this study was the total number of platelet transfusions required by each patient during the transplant course. Historical information was obtained from 90 women with breast cancer who had undergone ABMT with PBPC support at Duke University Medical Center. This information was used to estimate the mean, median, and variance of this patient cohort. The average number of transfusions during hematologic recovery for this group was 9.6, with a SD ϭ 5.6. The median number of transfusions was 8.0, indicating a right-skewed distribution and a range spanning from 0 to 27 transfusions. On the basis of these historical data, 75 evaluable patients were required to provide Ͼ80% power to detect a mean reduction of at least five platelet transfusions with either rhIL-11 dose compared with placebo, using a two-sided t-test with a significance level p ϭ 0.05. The placebo group was compared with each of the rhIL-11 groups by Dunnett's t-test. Because no statistically significant differences from placebo were detected, the rhIL-11 groups were combined and t-tests were used to characterize differences between the rhIL-11 and placebo groups in a descriptive fashion.
The statistical analysis was done on the 75 patients who received the study drug and not on the 80 patients randomized. When the statistical analysis was done on all 80 patients, however, the intent-to-treat analysis was unchanged from the results reported in this report.
RESULTS
Patient characteristics
A total of 80 patients were randomized over a period of 22 months. As shown in Table 1 , the treatment groups were
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comparable in terms of demographic or baseline characteristics. Distribution of cancer stage was similar among treatment groups, with over 60% of patients in all three groups having stage IIIB or metastatic disease.
Patient disposition
Of the 80 patients randomized, 75 (94%) received at least one dose of masked study drug. Of these 75 patients, 62 (83%) completed the study (21 of 26 in the placebo group, 22 of 28 in the 25-g/kg rhIL-11 group, and 19 of 26 in the 50-g/kg rhIL-11 group). The demographic and baseline characteristics of the patients who withdrew were representative of the study population as a whole.
Efficacy
As shown in Table 2 , the mean number of transfusions was 12.4 per patient in the placebo group vs. 9.2 for the 25-g/kg rhIL-11 group and 9.9 for the 50-g/kg rhIL-11 group. Although the mean values were lower in the rhIL11-treated groups, these results did not show a statistically significant difference from placebo. In the placebo group, the variability in the number of platelet transfusions was significantly greater than that in the rhIL-11 groups, with SD of 10.2 for the placebo group vs. only 5.0 for the 25-g/kg rhIL-11 group and 3.5 for the 50-g/kg rhIL-11 group ( p Ͻ 0.001).
Of the 16 alloimmunized patients (i.e., with positive HLA cytotoxic antibody test results and requiring HLAmatched platelets for transfusions), 13 were already alloimmunized at study entry (as evidenced by positive HLA cytotoxic test results). Of these 13 patients, only one was randomized to the placebo group and the remaining 12 were in the rhIL-11 groups (5 in the 25-g/kg and 7 in the 50-g/kg group). Three patients (one in the placebo group and one in each of the rhIL-11 groups) became alloimmunized during the study. As shown in Table 3 , alloimmunized patients tended to require more platelet transfusions than did nonalloimmunized patients, despite a lower platelet count threshold for transfusion, presumably because of reduced survival of transfused platelets.
Of the 25 patients in the placebo group, five (20%) had delayed platelet engraftment (no engraftment 30 days after ABMT) vs. three of 50 (6%) in the rhIL-11 groups.
The median number of days to platelet recovery (defined as the time from the first day of PBPC infusion to the day of the first of three consecutive platelet counts Ն20,000 cells/L) was 13 days for the placebo group vs. 13.5 for the combined rhIL-11 group.
The absolute platelet reticulocyte (reticulated platelet) count has been shown to measure indirectly the rate of platelet production [12] . In this study, the recovery of platelet reticulocytes was similar among treatment groups (Fig. 2) , and platelet reticulocytes began increasing several days before the recovery of platelet counts and the achievement of platelet transfusion independence. This result is consistent with observations showing that an increase in platelet reticulocytes is predictive of imminent platelet recovery following myelosuppressive chemotherapy and stem cell support.
Safety
Overall, rhIL-11 was well tolerated in this population. The incidence of adverse events was similar in the three treatment groups (Table 4) , and there were no statistically significant ( p Ͻ 0.05) differences between the IL-11 and placebo groups with grade 3 or 4 adverse events.
The most commonly recorded adverse events (neutropenic fever, chills, asthenia, fever, and pain) were those often associated with chemotherapy, and their incidences were comparable in the placebo and rhIL-11 groups. Table 4 presents adverse events significantly associated with rhIL-11 treatment. Peripheral edema (grade 1 or 2) has been observed in other studies and is due to plasma volume expansion related to sodium and water retention [13, 14] . Conjunctival bleeding (almost all grade 1) was asymptomatic and of no clinical consequence. Of the 15 patients in the rhIL-11 groups with conjunctival bleeding, eight were alloimmunized and 11 had platelet counts below 20,000 cells/L at the time of conjunctival bleeding (vs. none in the placebo group). This result may be confounded by the imbalance in the number of alloimmunized patients among the treatment groups.
The incidence of fever was similar in the placebo and rhIL-11 groups (52 and 46%, respectively). Moreover, in patients receiving rhIL-11, fever was not usually associated with chills, as is often found with other cytokines [15] [16] [17] [18] [19] , confirming that, unlike some other cytokines, rhIL-11 does not cause fever. The incidence of other adverse events commonly associated with cytokines, such as bone pain and myalgia, was similar in the placebo and rhIL-11 groups.
There was no statistical association between the administration of rhIL-11 and the occurrence of atrial arrhythmias, and the results of Holter monitoring did not suggest an association between administration of rhIL-11 and atrial arrhythmias. However, there were five of 50 patients treated with rhIL-11 and one of 25 patients treated with placebo who developed atrial arrythemias; a larger study is required to determine if there is a significant association.
One patient in the placebo group died during the study. None of the patients treated with rhIL-11 died. The number of patients who experienced disease progression during the study was similar for all treatment groups.
As shown in Table 5 , the 11 patients who discontinued the study drug because of an adverse event were evenly distributed across treatment groups. Patient 050 (50 g/kg Alloimmunized patients tended to require more platelet transfusions than nonalloimmunized patients despite a lower platelet count threshold for transfusion.
Figure 2. Platelet reticulocytes vs. time by treatment group
The number of platelet reticulocytes (1000 cells/L) was determined by dual staining with monoclonal antibodies to CD34 and CD41 and flow cytometry for the three treatment groups: 25 g/kg, 50 g/kg, and placebo. 
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rhIL-11) was withdrawn because of an adverse event (ventricular pause), which occurred before the start of the study drug but was not identified until after the patient had already received the study drug. Review of Holter monitoring data recorded the day before starting the study drug showed episodes of type II second degree atrioventricular block and three episodes of ventricular standstill; the longest pause was 6.79 seconds. The patient was asymptomatic. The median number of days to neutrophil recovery to Ն500 cells/L was 10 days for both treatment groups (ranges, 9-30 for placebo and 8-30 for rhIL-11). The mean number of units of RBCs transfused was 4.5 (Ϯ4.0) for the placebo group and 4.6 (Ϯ2.2) for the rhIL-11 group. None of the patients tested developed antibodies to rhIL-11.
DISCUSSION
Thrombocytopenia after high-dose chemotherapy and hematopoietic progenitor cell support has become an increasingly significant problem. The use of growth factor-primed PBPCs has reduced the duration of neutropenia from a period of a few weeks to ϳ1 week. This has also resulted in a decrease in the requirement of the number of platelet units transfused. However, prolonged and severe periods of thrombocytopenia are still frequently encountered. The availability of myeloid colony-stimulating factors and erythropoietin have led to a further escalation in the doses of both old and new chemotherapeutic agents. Unfortunately, no hematopoietic growth factor to date has demonstrated the ability to reduce the degree of thrombocytopenia. Although effective therapy, platelet transfusions are inconvenient, expensive, potentially toxic, and associated with the risk of development of alloimmunization [20] and transmission of infectious diseases.
In two randomized placebo-controlled trials of rhIL-11 in patients with chemotherapy-induced thrombocytopenia, rhIL-11 treatment (50 g/kg SC once daily) prevented platelet transfusions in a significantly higher number of patients relative to placebo-treated patients [21, 22] . In both studies, patients had received chemotherapy with no dose reductions. Platelet transfusions were given for platelet counts Ͻ20,000 cells/L or, if clinically indicated, for bleeding. Although patients treated with rhIL-11 in the present study required fewer transfusions on average than those treated with placebo, the differences were not statistically significant. These results may have been due to factors unique to this study:
1) The study was designed to detect, with 80% power, a mean reduction of at least five platelet transfusions for either rhIL-11 group compared with placebo group. This assumed that the SD for the total number of platelet transfusions per patient was 5.6. However, the average SD was ϳ7 or 25% higher than projected. This higher SD reduced the power of the study from 80 to 58%, meaning that the study had a 42% probability of yielding an inconclusive result, even if treatment with rhIL-11 produced a mean reduction of five platelet transfusions. Therefore, a larger study may have yielded a more conclusive result.
2) There was an imbalance in the number of alloimmunized patients randomized to rhIL-11 compared with the placebo group. Of 13 patients already alloimmunized at study entry, 12 were randomized to rhIL-11 and of the three patients who became alloimmunized during the study, two were in the rhIL-11 groups. Alloimmunized patients generally require more platelet transfusions than nonalloimmunized patients and did so in this study. In addition, many of our alloimmunized patients had delayed platelet engraftment, likely from immune thrombocytopenia, and responded to corticosteroids ( J.J.V., W.P.P., unpublished observations). Data from the alloimmunized patients increased the mean and SD of the number of platelet transfusions required by each patient in the rhIL-11 groups. Because they require more platelet transfusions, alloimmunized patients may benefit most from an effective thrombopoietic agent. Future studies should account for this factor in the randomization.
This study demonstrated that rhIL-11 can be administered safely to patients with breast cancer after high-dose chemotherapy with hematopoietic progenitor cell support. The most significant adverse events were edema, tachycardia, hypotension, and conjunctival bleeding. rhIL-11 treatment has been associated with dilutional anemia with an increase in plasma volume possibly due to increased renal sodium and water reabsorption [13] . In this trial, patients were hydrated extensively during the phase of high-dose chemotherapy and thereafter were given supplemental fluid with other supportive treatment (electrolytes, antibiotics, antiemetics, and transfusions). Patients were transfused with packed RBCs to maintain a hematocrit of at least 42% (there was no difference in RBC transfusions among the treatment groups). The resultant edema can theoretically explain the low and statistically insignificant difference in the incidence of transient atrial fibrillation in the placebo and rhIL-11 groups. The use of diuretics was discouraged because of the potential for renal insufficiency after highdose chemotherapy that included cisplatin.
The numbers of patients with atrial arrhythmias, dyspnea, or congestive heart failure were similar and statistically not different in the placebo and rhIL-11 groups. The incidence of effects commonly associated with cytokines (e.g., fever, bone pain, myalgia) was similar for the placebo and rhIL-11 groups. There were no clinically or statistically significant differences in times to neutrophil recovery among the groups, suggesting that rhIL-11 does not add to the acceleration of neutrophil recovery stimulated by G-CSF in this setting. It would also seem that rhIL-11 does not have any detrimental effect on neutrophil recovery when given concomitantly with G-CSF. This result is consistent with data on neutrophil recovery in other randomized placebo-controlled studies [21, 22] .
The recovery of platelet reticulocytes was similar among treatment groups, and platelet reticulocytes began increasing several days before the recovery of platelet counts and the achievement of platelet-transfusion independence. This result is consistent with observations showing that an increase in platelet reticulocytes is predictive of imminent platelet recovery following myelosuppressive chemotherapy and stem cell support.
Overall, the trend toward lower platelet transfusion requirements in the rhIL-11 groups than in the placebo group, the smaller SD of the number of platelet transfusions given to patients in the rhIL-11 groups, and a lower percentage of patients with delayed platelet engraftment in the rhIL groups despite the greater number of alloimmunized patients in the rhIL-11 groups suggest that rhIL-11 may be more effective in patients who are destined to have delayed platelet recovery after high-dose chemotherapy with ABMT and PBPC support than in those who are going to have relatively rapid recovery without a thrombopoietic agent. This promising possibility will require further study in patients who have a risk of delayed recovery after ABMT or after PBPC transplantation.
In conclusion, we have shown that rhIL-11 can be safely administered at either 25 or 50 g/kg/day for up to 21 days after high-dose chemotherapy with autologous hematopoietic progenitor cell support in patients with breast cancer. rhIL-11 resulted in a decrease in the number of platelet transfusions required, but that difference was not statistically significant. Future studies should stratify patients according to whether they are or are not alloimmunized. Regimens containing prolonged administration of IL-11 for more than 21 days should be evaluated for their effects on delayed platelet engraftment after high-dose chemotherapy.
